Patent intelligence · US
US 12428408
Fused heterocyclic mescaline derivatives
Fused heterocyclic mescaline derivatives
Patent details — US 12428408
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 30, 2025
- Expiration
- Sep 25, 2045
- Applicant
- Enveric Biosciences Canada Inc.
- Claims
- 19
- CPC classes
- A61P, A61P25/00
Quick answer
US 12428408 (Fused heterocyclic mescaline derivatives) is held by Enveric Biosciences Canada Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Enveric Biosciences Canada Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61P, A61P25/00
More from Enveric Biosciences Canada Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12378195
Aminated psilocybin derivatives and methods of using
granted -
US 12358885
Substituted n-propylamine fused heterocyclic mescaline derivatives
granted -
US 12338231
N-heterocycle substituted tryptamine derivatives and methods of using
granted -
US 12195439
C1-substituted isopropylamine fused heterocyclic mescaline derivatives
granted -
US 12187679
Hydroxylated psilocybin derivatives and methods of using
granted -
US 12138276
Halogenated psilocybin derivatives and methods of using
granted -
US 12133856
Multi-substituent psilocybin derivatives and methods of using
granted
Frequently asked questions
What is US patent 12428408?
US 12428408 (Fused heterocyclic mescaline derivatives) is held by Enveric Biosciences Canada Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12428408?
Enveric Biosciences Canada Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 22 pharmaceutical patents for this assignee.
When does US 12428408 expire?
Our index shows an expiration date of Sep 25, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.